Received: 8 September 2020
Accepted: 23 November 2020
First Online: 1 December 2020
Ethics approval and consent to participate
: Institutional ethics approval for this study was obtained from Shanghai General Hospital Ethics Committee (2016KY220). Participants enrolled in the study provided written informed consent to participate.
: Not applicable.
: DJH has received honoraria from Novartis and research funding from NanoMab Technology Limited. GC provides consultancy for NanoMab Technology Limited. VG has received research support from Siemens Healthcare. GJRC has received research support from NanoMab Technology Ltd., Theragnostics Ltd. and Serac Healthcare Ltd. and provides consultancy for GE Healthcare and NanoMab Technology Ltd.